Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study-Reference-Cited by-同舟云学术

Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study

Published:2022-04-08 Issue:6 Volume:34 Page:646-654
ISSN:0954-691X
Container-title:European Journal of Gastroenterology & Hepatology
language:en
Short-container-title:

Author:

Ferrante Marc,Schirbel Anja,Pierik Marieke J.,Haas Thomas,Flamant Mathurin,Khalifa Ahmed,Philip George,Cornillie Freddy,Meehan Alan G.,Govoni Marinella

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference16 articles.

1. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.;Sandborn;Gastroenterology,2014

2. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.;Sandborn;Gastroenterology,2014

3. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.;Schroeder;N Engl J Med,1987

4. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.;Lewis;Inflamm Bowel Dis,2008

5. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.;Jairath;Aliment Pharmacol Ther,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study;Digestive and Liver Disease;2024-01